What is the ticker symbol for TScan Therapeutics?

TScan Therapeutics trades under the ticker TCRX on NASDAQ.

What sector does TScan Therapeutics operate in?

TScan Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze TCRX in a portfolio?

PortView shows TCRX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

TScan Therapeutics (TCRX) Stock Analysis

NASDAQHealthcareBiotechnology

$0.42-36.95%

1-year price historyRange $0.42 – $2.52

52-week range$0.42

$0.42$2.57

What TScan Therapeutics does

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Key metrics

Market cap

$25.66M

P/E (TTM)

-0.46

EPS (TTM)

$-0.91

Beta

1.07

Dividend yield

0.00%

Revenue / share

$0.05

50-day avg

$0.86

200-day avg

$1.01

52-week high

$2.57

52-week low

$0.42

CEO

Gavin MacBeath

ETFs linked to TCRX

Broad-market and Healthcare sector ETFs an investor holding TScan Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

SPY — SPDR S&P 500 ETF Trust VOO — Vanguard S&P 500 ETF QQQ — Invesco QQQ Trust VTI — Vanguard Total Stock Market ETF

PortView Portfolio Insights

PortView analyzes how TCRX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze TCRX in PortView →

Similar companies

JNJ — Johnson &LLY — Eli Lilly A — Agilent Technologies ABBV — AbbVie Inc.ABT — Abbott Laboratories ALNY — Alnylam Pharmaceuticals

Frequently asked questions

What is the ticker symbol for TScan Therapeutics?: TScan Therapeutics trades under the ticker TCRX on NASDAQ.
Which exchange is TCRX listed on?: TCRX is listed on NASDAQ.
What sector does TScan Therapeutics operate in?: TScan Therapeutics is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze TCRX in a portfolio?: PortView shows TCRX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.